Mary Lynne Hedley

Dr. Hedley has served as the President and a member of the board of directors of TESARO, Inc., a pharmaceutical company, since co-founding the company in March 2010 and which was acquired by GlaxoSmithKline plc in January 2019. From July 2009 to February 2010, Dr. Hedley served as Executive Vice President of Operations and Chief Scientific Officer of Abraxis BioScience, a biotechnology company. Dr. Hedley served as Executive Vice President of Eisai Corporation of North America from January 2008 until July 2009, following the company’s acquisition of MGI PHARMA in January 2008. Dr. Hedley served in various positions at MGI PHARMA from 2004 through its acquisition in January 2008, most recently as Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Hedley co-founded and served as the President and Chief Executive Officer of ZYCOS, a biotechnology company, which was acquired by MGI PHARMA in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University and earned her bachelor of science degree in microbiology from Purdue University and her doctoral degree in immunology from the University of Texas, Southwestern Medical Center. She mentors undergraduate science students at Harvard University and Boston University and also serves on the Boards of Directors of bluebird bio, Millendo Therapeutics and Youville Place, an assisted living facility. She served on the Board of Directors for Receptos until its acquisition by Celgene.